직장에 발생한 위장관간질종양의 감량치료를 위한 Imanitib 선행치료

• 영문명: Neoadjuvant imatinib mesylate for debulking therapy of rectal gastrointestinal stromal tumor
• 발행기관: 조선대학교 의학연구원
• 저자명: 이준형(Jun Hyung Lee) 이준(Jun Lee) 김성중(Seong Jung Kim)
• 간행물 정보: 『The Medical Journal of Chosun University』제44권 제1호, 62~65쪽, 전체 4쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 2019.04.30

영문 초록

Gastrointestinal stromal tumor (GIST) is the most common soft tissue sarcoma of the gastrointestinal tract. Surgery is the primary treatment of choice for patients with localized or potentially resectable GIST, whereas imatinib is the main treatment for patients with advanced, unresectable, or metastatic GIST. Neoadjuvant treatment with imatinib is not routinely recommended unless there is significant justification for reducing the tumor size in order to improve surgical outcome. The authors describe a case of a 48-year-old man who confirmed huge rectal GIST, and received successful neoadjuvant treatment with imatinib for preserving anal sphincter function followed by transanal excision.

목차

서론

증례

고찰

키워드

Gastrointestinal stromal tumor Imatinib mesylate Neoadjuvant therapy Surgery